Skip to main content
SpringerLink
Log in

Impact of hospital pharmacist interventions on the combination of citalopram or escitalopram with other QT-prolonging drugs

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background Citalopram and escitalopram can both induce dose-dependent QT prolongation. The risk of arrhythmia may be increased with concomitant use of other drugs that induce QT prolongation. Objective To evaluate the prevalence and impact of pharmacist interventions on the combination of citalopram or escitalopram with other drugs that induce QT prolongation. Setting A French hospital with 517 computerized beds. Method All cardiac adverse drug reactions (ADRs) related to citalopram or escitalopram reported to the French pharmacovigilance database (FPDB) were analyzed. Then, over a 6-month period, all computerized prescriptions including citalopram or escitalopram and drug–drug interactions (DDI) were analyzed by pharmacists using a computerized provider order entry system (DXCare®, Medasys). Results Only 27 cardiac ADRs related to citalopram or escitalopram were reported in the database. Among the 57,857 prescriptions and 2116 contraindicated DDIs (3.7 %) that were analyzed. 444 DDIs (0.8 %) were considered to be clinically relevant by pharmacists and physicians and 168 (i.e., approximately 30 %) were related to a combination including citalopram or escitalopram. Most of the prescriptions related to DDIs including citalopram or escitalopram were discontinued in response to a pharmacist intervention when initiated during the hospital stay. Conclusion A high number of hospital prescriptions including citalopram or escitalopram with another QT-prolonging drug occurred, highlighting the importance of involvement of clinical pharmacists in prevention of potential ADRs related to such contraindications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Sultana J, Cutroneo P, Trifiro G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother. 2013;4(Suppl 1):S73–7.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Sikdar KC, Dowden J, Alaghehbandan R, MacDonald D, Peter P, et al. Adverse drug reactions in elderly hospitalized patients: a 12-year population-based retrospective cohort study. Ann Pharmacother. 2012;46(7–8):960–71.

    Article  PubMed  Google Scholar 

  3. Tache SV, Sonnichsen A, Ashcroft DM. Prevalence of adverse drug events in ambulatory care: a systematic review. Ann Pharmacother. 2011;45(7–8):977–89.

    Article  PubMed  Google Scholar 

  4. Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf. 2015;38(5):437–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Lazarou J, Pomeranz B, Corey P. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;79:1200–5.

    Article  Google Scholar 

  6. Trifiro G, Pariente A, Coloma PM, Kors JA, Polimeni G, et al. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoepidemiol Drug Saf. 2009;18(12):1176–84.

    Article  PubMed  Google Scholar 

  7. Lam R. Antidepressants and QTc prolongation. J Psychiatry Neurosci. 2013;38(2):E5–6.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Hasnain M, Howland RH, Vieweg WV. Escitalopram and QTc prolongation. J Psychiatry Neurosci. 2013;38(4):E11.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Álvarez E, Vieira S, Garcia-Moll X. Citalopram, escitalopram and prolonged QT: warning or alarm? Rev Psiquiatr Salud Ment. 2014;7(3):147–50.

    Article  PubMed  Google Scholar 

  10. Coughtrie A, Behr E, Layton D, Marshall V, Camm AJ, et al. Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort. BMJ Open. 2017;7(10):e016627.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Leape LL, Bates DW, Cullen DJ, Cooper J, Demonaco HJ, et al. Systems analysis of adverse drug events. ADE Prevention Study Group. JAMA. 1995;274(1):35–43.

    Article  CAS  PubMed  Google Scholar 

  12. Johnell K, Klarin I. The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf. 2007;30(10):911–8.

    Article  PubMed  Google Scholar 

  13. Barrons R. Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm. 2004;61(4):380–5.

    Article  Google Scholar 

  14. Kannry J. Effect of e-prescribing systems on patient safety. Mt Sinai J Med. 2011;78(6):827–33.

    Article  PubMed  Google Scholar 

  15. Kaushal R, Kern LM, Barron Y, Quaresimo J, Abramson EL. Electronic prescribing improves medication safety in community-based office practices. J Gen Intern Med. 2010;25(6):530–6.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Nuckols TK, Smith-Spangler C, Morton SC, Asch SM, Patel VM, et al. The effectiveness of computerized order entry at reducing preventable adverse drug events and medication errors in hospital settings: a systematic review and meta-analysis. Syst Rev. 2014;3:56.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Footracer KG. Alert fatigue in electronic health records. JAAPA. 2015;28(7):41–2.

    Article  PubMed  Google Scholar 

  18. Bates DW, Leape LL, Cullen DJ, Laird N, Petersen LA, et al. Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. JAMA. 1998;280(15):1311–6.

    Article  CAS  PubMed  Google Scholar 

  19. Bobb A, Gleason K, Husch M, Feinglass J, Yarnold PR, et al. The epidemiology of prescribing errors: the potential impact of computerized prescriber order entry. Arch Intern Med. 2004;164(7):785–92.

    Article  PubMed  Google Scholar 

  20. Anthierens S, Tansens A, Petrovic M, Christiaens T. Qualitative insights into general practitioners views on polypharmacy. BMC Fam Pract. 2010;11:65.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89(11):1363–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Tampi RR, Balderas M, Carter KV, Tampi DJ, Moca M, et al. Citalopram, QTc prolongation, and torsades de pointes. Psychosomatics. 2015;56(1):36–43.

    Article  PubMed  Google Scholar 

  23. Funk KA, Bostwick JR. A comparison of the risk of QT prolongation among SSRIs. Ann Pharmacother. 2013;47(10):1330–41.

    Article  CAS  PubMed  Google Scholar 

  24. Wisniowska B, Tylutki Z, Wyszogrodzka G, Polak S. Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect—comprehensive overview of clinical trials. BMC Pharmacol Toxicol. 2016;17:12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Li M, Ramos LG. Drug-induced QT prolongation and torsades de pointes. P T. 2017;42(7):473–7.

    PubMed  PubMed Central  Google Scholar 

  26. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385–96.

    Article  PubMed  Google Scholar 

  27. Pushkin R, Frassetto L, Tsourounis C, Segal ES, Kim S. Improving the reporting of adverse drug reactions in the hospital setting. Postgrad Med. 2010;122(6):154–64.

    Article  PubMed  Google Scholar 

  28. Khan SA, Goyal C, Chandel N, Rafi M. Knowledge, attitudes, and practice of doctors to adverse drug reaction reporting in a teaching hospital in India: an observational study. J Nat Sci Biol Med. 2013;4(1):191–6.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Allen LaPointe NM, Curtis LH, Chan KA, Kramer JM, Lafata JE, et al. Frequency of high-risk use of QT-prolonging medications. Pharmacoepidemiol Drug Saf. 2006;15(6):361–8.

    Article  PubMed  Google Scholar 

  30. Meid AD, Bighelli I, Machler S, Mikus G, Carra G, et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol. 2017;7(12):251–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

None.

Author information

Author notes

  1. T.T. Phan Thi and Y. Bézie contributed equally to this work.

Authors and Affiliations

  1. Pharmacy Department, Groupe hospitalier Paris Saint-Joseph, 185 rue Raymond Losserand, 75014, Paris, France

    A. Chastang, S. Renet, J. Corny, A. Petre, T. T. Phan Thi & Y. Bézie

  2. Clinical Pharmacy Department, University Paris Saclay, Paris, France

    S. Renet

  3. Clinical Research Center, Groupe hospitalier Paris Saint-Joseph, 185 rue Raymond Losserand, 75014, Paris, France

    H. Beaussier

  4. Centre Régional de PharmacoVigilance, Hôpital Européen Georges Pompidou, 20 Rue Leblanc, 75015, Paris, France

    A. Lillo-Lelouet

Authors
  1. A. Chastang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Renet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Corny
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Beaussier
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Petre
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Lillo-Lelouet
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T. T. Phan Thi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y. Bézie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y. Bézie.

Ethics declarations

Conflicts of interest

The authors declare no conflicts of interest.

Funding

None to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chastang, A., Renet, S., Corny, J. et al. Impact of hospital pharmacist interventions on the combination of citalopram or escitalopram with other QT-prolonging drugs. Int J Clin Pharm 41, 42–48 (2019). https://doi.org/10.1007/s11096-018-0724-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-018-0724-7

Keywords

Search

Navigation